Live Breaking News & Updates on James salierno

Stay informed with the latest breaking news from James salierno on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in James salierno and stay connected to the pulse of your community

Number of Shares and Voting Rights of ADOCIA as of June 30th, 2021

Number of Shares and Voting Rights of ADOCIA as of June 30th, 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Lacassagne , Midi-pyrées , France , French , James-salierno , Glargine-liraglutide , Pramlintide-biochaperone , Raimund-gabriel , Ruth-group , Mc-services , Adocia-press-relations-europe , Regulatory-news

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes

Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Canada , Paris , France-general- , France , Ahmad-haidar , James-salierno , Olivier-soula , Glargine-liraglutide , Pramlintide-biochaperone , Raimund-gabriel , Ruth-group , Mc-services

ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions

ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , Paris , France-general , France , American , James-salierno , Gregory-meiffren , Glargine-liraglutide , Pramlintide-biochaperone , Raimund-gabriel , Ruth-group , Mc-services

Number of Shares and Voting Rights of ADOCIA as of May 31st, 2021

Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF")

Lacassagne , Midi-pyrées , France , French , Pramlintide-biochaperone-lispro , Biochaperone-lispro , Biochaperone-glargine-liraglutide , James-salierno , Raimund-gabriel , Ruth-group , Mc-services , Adocia-press-relations-europe

ADOCIA Reinforces Its Board of Directors with the Appointment of Three New Independent Members

Regulatory News: ADOCIA (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides, announces

New-york , United-states , Paris , France-general , France , Boissel , Rhôalpes , Virginia , Columbia-university , Ponts , Haute-normandie , Pramlintide-biochaperone-lispro

Arbor Realty Trust, Inc. Announces Redemptions of Outstanding Cumulative Redeemable Preferred Stock

Arbor Realty Trust, Inc. Announces Redemptions of Outstanding Cumulative Redeemable Preferred Stock
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , Uniondale , American , Freddie-mac-optigo , Paul-elenio , Exchange-commission , Company-annual-report-on-form , Arbor-realty , Ruth-group-daniel-kontoh-boateng-james-salierno , Arbor-realty-trust-inc , American-stock-transfer-trust-company

ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021


ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021
ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC the
company) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, confirms that it will hold its Annual General Meeting ("AGM") on May 20, 2021 at 10:00 a.m., at Adocia's offices, 115 avenue Lacassagne, 69003, Lyon, France.
The Shareholders' Meeting will also be broadcast live on the Company's website (www.adocia.com under "Investors Shareholder Meeting") by audio webcast via conference call without possibility to interact.
The video will be available on a deferred basis within the timeframe provided for by the regulations.

Lacassagne , Midi-pyrées , France , Paris , France-general , Biochaperone-lispro , James-salierno , Pramlintide-biochaperone , Raimund-gabriel , Ruth-group , Mc-services , Adocia-press-relations-europe

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial


Share this article
Share this article
HOUSTON, April 6, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the engagement of IQVIA Biotech, a contract research organization (CRO) to manage the Company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.
"Our teaming up with IQVIA, a preeminent, global CRO, is intended to facilitate the advancement into possible clinical trials for WP1122 with the objective of determining our drug's potential for treating COVID-19," commented Walter Klemp, Moleculin's Chairman and CEO. "We continue to believe the best possible pathway for development may be outside the US, given the FDA's requirement that we complete an analysis in a COVID-19 animal model before submitting a request for US investigational new drug (IND) status.  Unfortunately, validated COVID-19 animal models are in high demand, resulting in a long lead time before that can be done.  In the meantime, we believe all of the necessary preclinical safety testing has now been completed to qualify for the equivalent of an IND outside the US. Over the last quarter, we completed our pre-clinical data, interviewed CRO's and decided that IQVIA Biotech has the experience and reach to best serve our clinical needs for this project. In addition, considering that the active ingredient in WP1122 is 2-deoxy-D-glucose (2-DG) and that 2-DG has now shown efficacy in a Phase 2 clinical trial conducted by an unrelated drug developer outside of the US, we believe that a sufficient efficacy rationale for WP1122 already exists to begin clinical trials."

Houston , Texas , United-states , Walter-klemp , James-salierno , Exchange-commission , Moleculin-biotech-inc , Securities-exchange , Nasdaq , Moleculin-biotech , Next-generation-anthracycline , Transcription-modulator

Number of Shares and Voting Rights of ADOCIA as of February 28th, 2021


Number of Shares and Voting Rights of ADOCIA as of February 28th, 2021
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (
Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French
société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of February 28th, 2021.
Month
9 773 093
(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

Lacassagne , Midi-pyrees , France , French , James-salierno , Pramlintide-biochaperone , Raimund-gabriel , Ruth-group , Mc-services , Adocia-press-relations-europe , Regulatory-news , French-code-de-commerce

Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results
Evoke Pharma, Inc.March 11, 2021 GMT
SOLANA BEACH, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter ended December 31, 2020 and recent corporate developments.
“Despite the challenges precipitated by the COVID-19 pandemic, 2020 proved to be a transformative year for Evoke as we initiated the commercial launch of GIMOTI™ for acute and recurrent diabetic gastroparesis with our commercial partner EVERSANA,” stated David A. Gonyer, R.Ph., President and CEO of Evoke Pharma. “We are encouraged by the early traction we are seeing in GIMOTI sales and the feedback we are receiving from gastroenterologists, which was further illustrated by the positive data observed in our market research study. We believe GIMOTI offers a distinct advantage over oral metoclopramide formulations as it is currently the only outpatient non-oral treatment option to help improve the quality of life for patients suffering with diabetic gastroparesis. We look forward to further addressing this significant medical need for the up to 16 million patients suffering from these symptoms as we continue to build sales traction.”

United-states , Davida-gonyer , Annika-parrish , Christine-petraglia-james-salierno , Exchange-commission , Ruth-group , Pharma-inc , Life-science-services , Nasdaq , Recent-progress , Evoke-assist , Full-year